biostudies-literatureUnknown5(4)Gulikers JL<h4>Introduction</h4>Brain metastases (BM) are common in patients with advanced <i>EGFR</i>-mutated (<i>EGFR</i>m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C_min,SS) and consequently limited intracranial osimertinib exposure. We investigated the relation between osimertinib C_min,SS and BM development or progression.<h4>Methods</h4>A prospective multicenter cohort study, including patients receiving osimertinib for advanced <i>EGFR</i>m<i>+</i> NSCLC. At osimertinib start, patients were allocated to the BM or no or unknown BM cohort and were further divided into subgroups based on osimertinib C_min,SS (low, middle, and high exposure). Cumulative incidence of BM progression or development and overall survival were determined for each group.<h4>Results</h4>A total of 173 patients were included, with 49 (28.3%) had baseline BM. Of these patients, 36.7% experienced BM progression, of which 16.7% in the low (<159.3 ng/mL), 40.0% in the middle, and 47.1% in the high (>270.7 ng/mL) C_min,SS subgroups. After 12 months, the cumulative incidence of BM progression for the BM cohort was 20% (95% confidence interval [CI] 2.6-49.0), 31% (95% CI:10.6-53.9), and 31% (95% CI:10.8-54.5) per C_min,SS subgroup, respectively. After 20 months, this was 20% (95% CI:2.6-49.0), 52% (95% CI:23.8-74.2), and 57% (95% CI:24.9-79.7), respectively. For the no or unknown BM cohort, 4.0% developed BM without differences within C_min,SS subgroups.<h4>Conclusions</h4>No relation was found between osimertinib C_min,SS and BM development or progression in patients with advanced <i>EGFR</i>m<i>+</i> NSCLC. This suggests that systemic osimertinib exposure is not a surrogate marker for BM development or progression.JTO clinical and research reports100656https://www.ebi.ac.uk/biostudies/studies/S-EPMC10973185biostudies-literatureOsimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLC.PMC10973185Kruithof PDDursun SMathijssen RHJTjan-Heijnen VCGJebbink MHendriks LELVeerman GDMDriessen JHMCroes SDingemans ACSteendam CMJGulikers JLBoosman RJSmit EFvan Geel RMJMfalseOsimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced <i>EGFR</i>-Mutated NSCLC.<h4>Introduction</h4>Brain metastases (BM) are common in patients with advanced <i>EGFR</i>-mutated (<i>EGFR</i>m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C_min,SS) and consequently limited intracranial osimertinib exposure. We investigated the relation between osimertinib C_min,SS and BM development or progression.<h4>Methods</h4>A prospective multicenter cohort study, including patients receiving osimertinib for advanced <i>EGFR</i>m<i>+</i> NSCLC. At osimertinib start, patients were allocated to the BM or no or unknown BM cohort and were further divided into subgroups based on osimertinib C_min,SS (low, middle, and high exposure). Cumulative incidence of BM progression or development and overall survival were determined for each group.<h4>Results</h4>A total of 173 patients were included, with 49 (28.3%) had baseline BM. Of these patients, 36.7% experienced BM progression, of which 16.7% in the low (<159.3 ng/mL), 40.0% in the middle, and 47.1% in the high (>270.7 ng/mL) C_min,SS subgroups. After 12 months, the cumulative incidence of BM progression for the BM cohort was 20% (95% confidence interval [CI] 2.6-49.0), 31% (95% CI:10.6-53.9), and 31% (95% CI:10.8-54.5) per C_min,SS subgroup, respectively. After 20 months, this was 20% (95% CI:2.6-49.0), 52% (95% CI:23.8-74.2), and 57% (95% CI:24.9-79.7), respectively. For the no or unknown BM cohort, 4.0% developed BM without differences within C_min,SS subgroups.<h4>Conclusions</h4>No relation was found between osimertinib C_min,SS and BM development or progression in patients with advanced <i>EGFR</i>m<i>+</i> NSCLC. This suggests that systemic osimertinib exposure is not a surrogate marker for BM development or progression.2024-01-01T00:00:00Z2024 Apr2025-04-26T11:21:26.895Z2025-04-06T13:41:05.683ZS-EPMC109731853855029710.1016/j.jtocrr.2024.100656